arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Marker Therapeutics, Inc.

MRKR
$1.25 ▲ +0.04 (+3.31%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Marker Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $19.1M
Dividend Yield —
Revenue Growth -46.2% ↘
Op. Margin -363.5% ↘
ROIC -76.6% ↘
FCF / Share $-0.78 ↗
Trailing P/E —
Price / Book 1.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

26-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.55M
↓ -46.2% —
Net Income Profit after all expenses
$-12.16M
↓ -13.3% —
Operating Margin Operating profit as % of sales
-363.5%
↓ -115.5% 0th
FCF / Share Free cash flow per share
$-0.78
↑ +35.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↑
12
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 26 years · 73 quarters